DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today issued the following statement in response to the recent action taken by the U.S. Food and Drug Administration (FDA) to update the labeling for fenofibrate drugs in association with cardiovascular care: We applaud the FDA’s decision to revise the labeling of fenofibrates (fibrates). The updated labeling now includes a clear ...